Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) EBIT: 2016-2024

Historic EBIT for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to -$47.4 million.

  • Mereo BioPharma Group's EBIT fell 6.85% to -$10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.0 million, marking a year-over-year decrease of 19.83%. This contributed to the annual value of -$47.4 million for FY2024, which is 66.68% down from last year.
  • According to the latest figures from FY2024, Mereo BioPharma Group's EBIT is -$47.4 million, which was down 66.68% from -$28.4 million recorded in FY2023.
  • Over the past 5 years, Mereo BioPharma Group's EBIT peaked at -$28.2 million during FY2021, and registered a low of -$54.4 million during FY2022.
  • In the last 3 years, Mereo BioPharma Group's EBIT had a median value of -$47.4 million in 2024 and averaged -$43.4 million.
  • Its EBIT has fluctuated over the past 5 years, first slumped by 92.85% in 2022, then soared by 47.79% in 2023.
  • Over the past 5 years, Mereo BioPharma Group's EBIT (Yearly) stood at -$48.2 million in 2020, then soared by 41.50% to -$28.2 million in 2021, then crashed by 92.85% to -$54.4 million in 2022, then soared by 47.79% to -$28.4 million in 2023, then tumbled by 66.68% to -$47.4 million in 2024.